{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:50:18Z","timestamp":1795024218849,"version":"4.10.2"},"reference-count":99,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Adenoviral vectors, both oncolytic viruses and gene delivery vectors, are among the earliest approved and commercialised vectors for gene therapy. Adenoviruses have high cytotoxicity and immunogenicity. Therefore, lentiviruses or adeno-associated viruses as viral vectors and herpes simplex virus as an oncolytic virus have recently drawn attention. Thus, adenoviral vectors are often considered relatively obsolete. However, their high cargo limit and transduction efficiency are significant advantages over newer viral vectors. This review provides an overview of the new-generation adenoviral vectors. In addition, we describe the modification of the fiber knob region that enhances affinity of adenoviral vectors for cancer cells and the utilisation of cancer-cell-specific promoters to suppress expression of unwanted transgenes in non-malignant tissues.<\/jats:p>","DOI":"10.3390\/cimb45060307","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T10:08:41Z","timestamp":1685700521000},"page":"4826-4840","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Adenovirus as a Vector and Oncolytic Virus"],"prefix":"10.3390","volume":"45","author":[{"given":"Wataru","family":"Matsunaga","sequence":"first","affiliation":[{"name":"Joint-Use Research Facilities, Hyogo Medical University, 1-1 Mukogawa, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1203-9896","authenticated-orcid":false,"given":"Akinobu","family":"Gotoh","sequence":"additional","affiliation":[{"name":"Department of Education for Medical Research Base, Hyogo Medical University, 1-1 Mukogawa, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/s41598-018-37249-4","article-title":"Molecular Evolution of Human Adenovirus (HAdV) Species C","volume":"9","author":"Dhingra","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/ng0393-224","article-title":"Transfer of a foreign gene into the brain using adenovirus vectors","volume":"3","author":"Akli","year":"1993","journal-title":"Nat. Genet."},{"key":"ref_3","unstructured":"(2023, February 28). Gene Therapy Clinical Trials Worldwide. Available online: https:\/\/a873679.fmphost.com\/fmi\/webd\/GTCT."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jgm.2698","article-title":"Gene therapy clinical trials worldwide to 2012\u2014An update","volume":"15","author":"Ginn","year":"2013","journal-title":"J. Gene Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e3015","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: An update","volume":"20","author":"Ginn","year":"2018","journal-title":"J. Gene Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1172\/JCI35700","article-title":"Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1","volume":"118","author":"Garrigue","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Labb\u00e9, R.P., Vessillier, S., and Rafiq, Q.A. (2021). Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives. Viruses, 13.","DOI":"10.3390\/v13081528"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.virol.2004.10.012","article-title":"Two novel adeno-associated viruses from cynomolgus monkey: Pseudotyping characterization of capsid protein","volume":"330","author":"Mori","year":"2004","journal-title":"Virology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","article-title":"Addressing high dose AAV toxicity\u2014\u2018One and done\u2019 or \u2018slower and lower\u2019?","volume":"22","author":"Kishimoto","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"R36","DOI":"10.1093\/hmg\/ddv475","article-title":"Adeno-associated viral vectors for the treatment of hemophilia","volume":"25","author":"High","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Fajardo-Serrano, A., Rico, A.J., Roda, E., Honrubia, A., Arrieta, S., Ariznabarreta, G., Chocarro, J., Lorenzo-Ramos, E., Pejenaute, A., and V\u00e1zquez, A. (2021). Adeno-Associated Viral Vectors as Versatile Tools for Parkinson\u2019s Research, Both for Disease Modeling Purposes and for Therapeutic Uses. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126389"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fonc.2019.00052","article-title":"Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors","volume":"9","author":"Reul","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_15","unstructured":"(2023, January 19). FDA Approves Innovative Gene Therapy to Treat Pediatric Patients with Spinal Muscular Atrophy, A Rare Disease and Leading Genetic Cause of Infant Mortality. 24 May 2019, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","article-title":"Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial","volume":"20","author":"Day","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e00390-18","DOI":"10.1128\/mBio.00390-18","article-title":"Hacking the Cell: Network Intrusion and Exploitation by Adenovirus E1A","volume":"9","author":"King","year":"2018","journal-title":"mBio"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/viro.1997.8597","article-title":"Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line","volume":"233","author":"Louis","year":"1997","journal-title":"Virology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1002\/1873-3468.13682","article-title":"Immune evasion by adenoviruses: A window into host-virus adaptation","volume":"593","author":"Oliveira","year":"2019","journal-title":"FEBS Lett."},{"key":"ref_20","first-page":"867","article-title":"Common control of the heat shock gene and early adenovirus genes: Evidence for a cellular E1A-like activity","volume":"4","author":"Imperiale","year":"1984","journal-title":"Mol. Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2007.10.005","article-title":"Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications","volume":"132","author":"Hartman","year":"2008","journal-title":"Virus Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Saha, B., and Parks, R.J. (2017). Human adenovirus type 5 vectors deleted of early region 1 (E1) undergo limited expression of early replicative E2 proteins and DNA replication in non-permissive cells. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0181012"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1128\/JVI.77.9.5295-5304.2003","article-title":"Distinct roles of the adenovirus E4 ORF3 protein in viral DNA replication and inhibition of genome concatenation","volume":"77","author":"Evans","year":"2003","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1089\/hum.1998.9.11-1587","article-title":"Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery","volume":"9","author":"Zhou","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/gt.2008.14","article-title":"Progress and prospects: Gene therapy for genetic diseases with helper-dependent adenoviral vectors","volume":"15","author":"Ng","year":"2008","journal-title":"Gene Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1006\/mthe.2001.0323","article-title":"Development of a FLP\/frt system for generating helper-dependent adenoviral vectors","volume":"3","author":"Ng","year":"2001","journal-title":"Mol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.1563-2563.2002.02033.x","article-title":"Gutless adenoviral vectors\u2014Promising tools for gene therapy","volume":"34","author":"Jozkowicz","year":"2002","journal-title":"Eur. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.5483\/BMBRep.2020.53.11.185","article-title":"Helper virus-free gutless adenovirus (HF-GLAd): A new platform for gene therapy","volume":"53","author":"Liu","year":"2020","journal-title":"BMB Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0299-y","article-title":"No more helper adenovirus: Production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants","volume":"51","author":"Lee","year":"2019","journal-title":"Exp. Mol. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1128\/jvi.71.4.3293-3298.1997","article-title":"A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging","volume":"71","author":"Parks","year":"1997","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8027","DOI":"10.1128\/JVI.73.10.8027-8034.1999","article-title":"Effects of stuffer DNA on transgene expression from helper-dependent adenovirus vectors","volume":"73","author":"Parks","year":"1999","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8409","DOI":"10.1128\/JVI.00796-09","article-title":"Host cell detection of noncoding stuffer DNA contained in helper-dependent adenovirus vectors leads to epigenetic repression of transgene expression","volume":"83","author":"Ross","year":"2009","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1128\/JVI.76.4.1600-1609.2002","article-title":"Variables affecting in vivo performance of high-capacity adenovirus vectors","volume":"76","author":"Schiedner","year":"2002","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical trial","volume":"1","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.omto.2021.11.006","article-title":"Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance","volume":"23","author":"Green","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_36","unstructured":"(2023, May 22). FDA Approves First Gene Therapy for the Treatment of High-Risk, Non-Muscle-Invasive Bladder Cancer. (6 December 2022), Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-treatment-high-risk-non-muscle-invasive-bladder-cancer."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/hum.2017.114","article-title":"Double-Dose Adenovirus-Mediated Adjuvant Gene Therapy Improves Liver Transplantation Outcomes in Patients with Advanced Hepatocellular Carcinoma","volume":"29","author":"Zhu","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4161\/cbt.4.5.1820","article-title":"Viral oncolysis by herpes simplex virus and other viruses","volume":"4","author":"Kuruppu","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: Genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_40","first-page":"49","article-title":"Oncolytic Viruses as Cancer Therapeutic agents Current Status of Oncolytic Viruses","volume":"18","author":"Eto","year":"2017","journal-title":"J. Kyushu Univ. Health Welf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3389\/fonc.2020.01786","article-title":"The Oncolytic Virus in Cancer Diagnosis and Treatment","volume":"10","author":"Cao","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nm0697-639","article-title":"ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents","volume":"3","author":"Heise","year":"1997","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"ref_44","first-page":"6359","article-title":"Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial","volume":"60","author":"Nemunaitis","year":"2000","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world\u2019s first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J. Nat. Cancer Inst."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/OV.S100072","article-title":"Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma","volume":"6","author":"Babiker","year":"2017","journal-title":"Oncolytic Virother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_48","unstructured":"(2022, November 12). Press Release from Daiichi-Sankyo. 11 June 2021. Available online: https:\/\/www.daiichisankyo.co.jp\/files\/news\/pressrelease\/pdf\/202106\/20210611_J.pdf."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41417-019-0129-3","article-title":"Oncolytic activity of HF10 in head and neck squamous cell carcinomas","volume":"27","author":"Esaki","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1078-0432.CCR-1075-3","article-title":"Telomerase-specific replication-selective virotherapy for human cancer","volume":"10","author":"Kawashima","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.omto.2022.10.001","article-title":"An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma","volume":"27","author":"Gohara","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_52","unstructured":"(2022, December 23). Phase 2 Study of OBP-301 (Telomelysin\u2122) in Combination with Pembrolizumab and SBRT in Patients with HNSCC with Inoperable, Recurrent or Progressive Disease. 28 December 2020, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04685499."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"707290","DOI":"10.3389\/fmicb.2021.707290","article-title":"Oncolytic Adenovirus: Prospects for Cancer Immunotherapy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Microbiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.juro.2006.10.034","article-title":"A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells","volume":"177","author":"Okegawa","year":"2007","journal-title":"J. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Hensen, L.C.M., Hoeben, R.C., and Bots, S.T.F. (2020). Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186828"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"9183","DOI":"10.1128\/JVI.77.17.9183-9191.2003","article-title":"Adenovirus type 11 uses CD46 as a cellular receptor","volume":"77","author":"Segerman","year":"2003","journal-title":"J. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0378-1119(02)00410-9","article-title":"Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes","volume":"285","author":"Mizuguchi","year":"2002","journal-title":"Gene"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1128\/JVI.74.6.2567-2583.2000","article-title":"Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector","volume":"74","author":"Shayakhmetov","year":"2000","journal-title":"J. Virol."},{"key":"ref_62","first-page":"1141","article-title":"Adenovirus vectors with chimeric type 5 and 35 fiber proteins exhibit enhanced transfection of human pancreatic cancer cells","volume":"33","author":"Toyoda","year":"2008","journal-title":"Int. J. Oncol."},{"key":"ref_63","first-page":"2311","article-title":"Adenovirus type 5 substituted with type 11 or 35 fiber structure increases its infectivity to human cells enabling dual gene transfer in CD46-dependent and independent manners","volume":"27","author":"Yu","year":"2007","journal-title":"Anticancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/sj.cgt.7700981","article-title":"Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting","volume":"13","author":"Ni","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omto.2021.01.015","article-title":"Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35","volume":"20","author":"Ono","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymthe.2006.01.010","article-title":"Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells","volume":"14","author":"Bauerschmitz","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/jmv.23325","article-title":"Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China","volume":"84","author":"Yu","year":"2012","journal-title":"J. Med. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","article-title":"Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy","volume":"4","author":"Havunen","year":"2017","journal-title":"Mol. Ther. Oncolyt."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"000188","DOI":"10.1136\/jitc-2019-000188","article-title":"Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity","volume":"8","author":"Santos","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/ijc.30228","article-title":"Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5\/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model","volume":"139","author":"Kuryk","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ymthe.2005.10.005","article-title":"Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity","volume":"13","author":"Barton","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/sj.gt.3301706","article-title":"The potential of 5-fluorocytosine\/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model","volume":"9","author":"Nyati","year":"2002","journal-title":"Gene Ther."},{"key":"ref_74","first-page":"5276","article-title":"Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy","volume":"46","author":"Moolten","year":"1986","journal-title":"Cancer Res."},{"key":"ref_75","first-page":"2145","article-title":"Intravesical chemo-immunotherapy in non-muscle invasive bladder cancer","volume":"17","author":"Leopardo","year":"2013","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2007.08.122","article-title":"History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story","volume":"179","author":"Herr","year":"2008","journal-title":"J. Urol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Chang, Y., Lin, W.Y., Chang, Y.C., Huang, C.H., Tzeng, H.E., Abdul-Lattif, E., Wang, T.H., Tseng, T.H., Kang, Y.N., and Chi, K.Y. (2022). The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15010284"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J. Immunother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/14712598.2011.558838","article-title":"Oncolytic vaccinia virus for the treatment of cancer","volume":"11","author":"Guse","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Mantwill, K., Klein, F.G., Wang, D., Hindupur, S.V., Ehrenfeld, M., Holm, P.S., and Nawroth, R. (2021). Concepts in Oncolytic Adenovirus Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910522"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1083\/jcb.110.3.607","article-title":"A retinoic acid responsive gene MK found in the teratocarcinoma system is expressed in spatially and temporally controlled manner during mouse embryogenesis","volume":"110","author":"Kadomatsu","year":"1990","journal-title":"J. Cell Biol."},{"key":"ref_83","first-page":"1814","article-title":"An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis","volume":"57","author":"Choudhuri","year":"1997","journal-title":"Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/bjc.1997.58","article-title":"Midkine induces the transformation of NIH3T3 cells","volume":"75","author":"Kadomatsu","year":"1997","journal-title":"Br. J. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/bph.12353","article-title":"Structure and function of midkine as the basis of its pharmacological effects","volume":"171","author":"Muramatsu","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.onc.1204026","article-title":"The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells","volume":"20","author":"Mashour","year":"2001","journal-title":"Oncogene"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1038\/s41467-022-32673-7","article-title":"Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment","volume":"13","author":"Tang","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1054\/bjoc.2000.1339","article-title":"Serum midkine levels are increased in patients with various types of carcinomas","volume":"83","author":"Ikematsu","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/modpathol.3880195","article-title":"Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma","volume":"13","author":"Kato","year":"2000","journal-title":"Mod. Pathol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/iub.2458","article-title":"Shedding more light on the role of Midkine in hepatocellular carcinoma: New perspectives on diagnosis and therapy","volume":"73","author":"Ezzatifar","year":"2021","journal-title":"IUBMB Life"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1093\/oxfordjournals.jbchem.a123797","article-title":"Genomic structure of human midkine (MK), a retinoic acid-responsive growth\/differentiation factor","volume":"111","author":"Uehara","year":"1992","journal-title":"J. Biochem."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"920.e7","DOI":"10.1016\/j.urology.2012.12.023","article-title":"Fiber-substituted conditionally replicating adenovirus Ad5F35 induces oncolysis of human bladder cancer cells in in vitro analysis","volume":"81","author":"Gotoh","year":"2013","journal-title":"Urology"},{"key":"ref_93","first-page":"4891","article-title":"Beneficial oncolytic effect of fiber-substituted conditionally replicating adenovirus on human lung cancer","volume":"32","author":"Kanno","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_94","first-page":"3743","article-title":"Gene therapy using adenovirus against malignant mesothelioma","volume":"32","author":"Gotoh","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_95","first-page":"2985","article-title":"Fiber-substituted conditionally replicating adenovirus for oncolysis of human renal carcinoma cells","volume":"32","author":"Nagaya","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.2015.067","article-title":"CRISPR\/Cas9-mediated genome editing of epigenetic factors for cancer therapy","volume":"26","author":"Yao","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"ref_97","first-page":"931","article-title":"CRISPR-Cas9, a promising therapeutic tool for cancer therapy: A review","volume":"27","author":"Akram","year":"2020","journal-title":"Protein Pept. Lett."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.21873\/anticanres.15164","article-title":"Cancer Cell-specific Transfection of hCas9 Gene Using Ad5F35 Vector","volume":"41","author":"Matsunaga","year":"2021","journal-title":"Anticancer Res."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/45\/6\/307\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:47:42Z","timestamp":1760125662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/45\/6\/307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":99,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["cimb45060307"],"URL":"https:\/\/doi.org\/10.3390\/cimb45060307","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,2]]}}}